Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50
values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro
. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
The citations listed below are publications that use Tocris products. Selected citations for Crizotinib include:
Showing Results 1 - 2 of 2